# CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

> **NCT05724355** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 32 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Dalpiciclib Isetionate Tablets, Camrelizumab

## Key facts

- **NCT ID:** NCT05724355
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2023-10
- **Final completion:** 2024-10
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724355, "CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05724355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*